Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Demeter

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Sexually Transmitted Diseases|July 1, 1996
Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatumW Bonnez, D Oakes, A Choi, et al.
Journal of Virology|August 13, 2011
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infectionJiong Wang, Gang Zhang, Robert A Bambara, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)L M Demeter, R W Shafer, P M Meehan, et al.
The Journal of Infectious Diseases|December 1, 1990
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trialR C Reichman, D Oakes, W Bonnez, et al.
Antimicrobial Agents and Chemotherapy|May 29, 1999
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 TeamM F Para, P Meehan, J Holden-Wiltse, et al.
AIDS (London, England)|December 31, 2008
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patientsLisa M Demeter, Hongyu Jiang, A Lisa Mukherjee, et al.
AIDS (London, England)|January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2014
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227Mary A Vogler, Laura M Smeaton, Rodney L Wright, et al.
Antiviral Research|April 25, 2000
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teamsG D Morse, R C Reichman, M A Fischl, et al.
HIV Clinical Trials|January 25, 2008
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experienceLisa M Demeter, Victor DeGruttola, Stephanie Lustgarten, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Sexually Transmitted Diseases|July 1, 1996
Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatumW Bonnez, D Oakes, A Choi, et al.
Journal of Virology|August 13, 2011
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infectionJiong Wang, Gang Zhang, Robert A Bambara, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)L M Demeter, R W Shafer, P M Meehan, et al.
The Journal of Infectious Diseases|December 1, 1990
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trialR C Reichman, D Oakes, W Bonnez, et al.
Antimicrobial Agents and Chemotherapy|May 29, 1999
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 TeamM F Para, P Meehan, J Holden-Wiltse, et al.
AIDS (London, England)|December 31, 2008
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patientsLisa M Demeter, Hongyu Jiang, A Lisa Mukherjee, et al.
AIDS (London, England)|January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2014
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227Mary A Vogler, Laura M Smeaton, Rodney L Wright, et al.
Antiviral Research|April 25, 2000
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teamsG D Morse, R C Reichman, M A Fischl, et al.
HIV Clinical Trials|January 25, 2008
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experienceLisa M Demeter, Victor DeGruttola, Stephanie Lustgarten, et al.
Pageof 9